ribavirin + abacavir

Ribavirin + abacavir is a combination of two antiviral small molecules used primarily in the management of patients coinfected with HIV and hepatitis C virus (HCV). Ribavirin is a synthetic guanosine nucleoside analog that acts as a broad-spectrum antiviral by interfering with viral RNA synthesis and mRNA capping, leading to inhibition of viral replication. It is mainly indicated for chronic hepatitis C and certain viral hemorrhagic fevers. Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) used in combination antiretroviral therapy for HIV infection; it works by being converted intracellularly to carbovir triphosphate, which inhibits HIV-1 reverse transcriptase through chain termination during DNA synthesis. The combination may be considered in patients coinfected with HIV/HCV, but there are potential drug interactions and increased risk of side effects when used together[1][2][3][4][5][6][8].

Brand names

ZiagenRibapak

Other names

abacavir + ribavirinABC + RBV